Cardinal Health reports its Q3 2026 results today against an uncomfortable backdrop: the stock is down nearly 7% over the past month, trading at $192.88, and the mean analyst price target of $247 implies roughly 28% upside — a gap that flatters a stock the Street has been quietly trimming on.
The most telling recent analyst move came from Evercore ISI, which cut its target from $260 to $240 earlier in April while keeping an Outperform rating — a classic "we still like it, but less so" posture that tends to precede broader reassessment. William Blair initiated with Outperform last week, adding a fresh bullish voice into the print. The broader analyst chorus remains constructive: the consensus sits well into buy territory, with 22% average upside to current targets. But the direction of travel matters. The post-Q2 wave of target raises — JPMorgan to $243, Wells Fargo to $256, Barclays to $258, Morgan Stanley to $245 — all came through in January and February. Since then, the only move has been a trim. Momentum on analyst sentiment has stalled.
The bull case centers on Cardinal's scale as a healthcare distribution backbone: $256 billion in estimated revenue, an EV/EBITDA around 13x, and a consistent track record of beating expectations — the stock popped 9.4% the day after its Q2 print in February. Bears point to the recent multiple compression, with the trailing P/E contracting by about a full turn over the past month, and the broader macro pressure facing healthcare distributors in a tariff-sensitive environment. The forward EPS growth percentile ranks only in the 33rd percentile across the universe, suggesting the Street sees limited earnings acceleration from here.
Short sellers are not pressing the stock hard into this print. Short interest is modest at 2.5% of the free float, essentially unchanged over the past month. Borrow availability is ample, and cost to borrow is just 0.40% — nowhere near the levels that would suggest crowded positioning or a lending squeeze. Options sentiment has actually shifted away from protection: the put/call ratio of 0.72 is slightly below its 20-day average of 0.76, now running about one standard deviation more call-heavy than usual. The RSI of 41 places CAH in mildly oversold territory but not at extremes. Peer distributors MCK and COR are each down only 1–2% on the week versus CAH's near-6% slide, making Cardinal's underperformance look stock-specific rather than sector-driven.
The Q3 print will test whether the post-Q2 optimism — which sent the stock above $230 — was justified, or whether the April selloff correctly anticipated weaker operational momentum at the distribution segment.
See the live data behind this article on ORTEX.
Open CAH on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
